Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03120832 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients
A Phase 1 study of Prostate Cancer, sponsored by Sensei Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 4
- Study locations
NCT03120832: Completed Phase 1 study of Prostate Cancer, sponsored by Sensei Biotherapeutics.
NCT03120832 is a Phase 1 study of Prostate Cancer that has completed, run by Sensei Biotherapeutics. The registered enrollment target is 12 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03120832, a Phase 1 study of Prostate Cancer, has completed, sponsored by Sensei Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose escalation schema every 21 days.
Conditions Studied
Interventions
- BIOLOGICAL PAN-301-1
Study Locations (4)
Alabama
- Urology Centers of Alabama - Homewood
California
- Dr. James J. Elist - Beverly Hills
Nebraska
- GU Research Network/Urology Cancer Center - Omaha
South Carolina
- Carolina Urologic Research Center - Myrtle Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-12 |
| Phase | Phase 1 |
What the finished NCT03120832 record still lists
NCT03120832 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which PAN-301-1 is the first listed.
NCT03120832 reports a single indexed study location in Alabama, California, Nebraska.
Frequently Asked Questions
What is clinical trial NCT03120832 about?
NCT03120832 is a clinical study titled "Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients". This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose escalation schema every 21 days.
What is the current status of trial NCT03120832?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-12. Estimated completion is 2018-12.
What conditions does trial NCT03120832 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03120832?
The interventions under investigation include: PAN-301-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03120832?
This trial is sponsored by Sensei Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03120832 being conducted?
This trial has 4 study locations across Alabama, California, Nebraska, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03120832's enrollment target sits among peer trials
12 703rd of 735 higher than 23 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia